Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males - a pilot study

Atherosclerosis

Volumn 215, Issue 2, 2011, Pages 446-451

  Lunder, Mojca ^a,b   Janić, Miodrag ^a   Habjan, Sara ^a   Šabovič, Mišo ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Apparently healthy males; Arterial stiffness; Cardiovascular prevention; Flow mediated dilation; Impaired endothelial function; Low dose fluvastatin; Middle age

Indexed keywords

FLUINDOSTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTERIAL STIFFNESS; ARTERY WALL; ARTICLE; BODY MASS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMMON CAROTID ARTERY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; FLOW MEDIATED DILATION; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; LOW DRUG DOSE; MALE; MIDDLE AGED; PILOT STUDY; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION; WAIST CIRCUMFERENCE;

ADULT; AGING; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; CAROTID ARTERY, COMMON; DILATATION, PATHOLOGIC; FATTY ACIDS, MONOUNSATURATED; HUMANS; INDOLES; MALE; MIDDLE AGED; PILOT PROJECTS; PLACEBOS; PULSATILE FLOW; VASCULAR RESISTANCE;

EID: 79953061592     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.12.041     Document Type: Article

References (30)

1. Grundy S.M. Age as a risk factor: you are as old as your arteries. Am J Cardiol 1999, 83:1455-1457.
2. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: Aging arteries a " set up" for vascular disease. Circulation 2003, 107:139-146.
3. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39:257-265.
4. Celermajer D.S., Sorensen K.E., Spiegelhalter D.J., Georgakopoulos D., Robinson J., Deanfield J.E. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994, 24:471-476.
5. O'Rourke M.F., Nichols W.W. Aortic diameter, aortic stiffness, and wave reflection increase with age and isolated systolic hypertension. Hypertension 2005, 45:652-658.
6. Vaitkevicius P.V., Fleg J.L., Engel J.H., et al. Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation 1993, 88:1456-1462.
7. Taddei S., Virdis A., Mattei P., et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995, 91:1981-1987.
8. Eskurza I., Kahn Z.D., Seals D.R. Xanthine oxidase does not contribute to impaired peripheral conduit artery endothelium-dependent dilatation with ageing. J Physiol 2006, 571:661-668.
9. Eskurza I., Monahan K.D., Robinson J.A., Seals D.R. Effect of acute and chronic ascorbic acid on flow-mediated dilatation with sedentary and physically active human ageing. J Physiol 2004, 556:315-324.
10. McEniery C.M., Wallace S., Mackenzie I.S., et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension 2006, 48:602-608.
11. Amar J., Ruidavets J.B., Chamontin B., Drouet L., Ferrieres J. Arterial stiffness and cardiovascular risk factors in a population-based study. J Hypertens 2001, 19:381-387.
12. Nichols W.W. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005, 18:3S-10S.
13. McVeigh G.E., Bratteli C.W., Morgan D.J., et al. Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis: aging and arterial compliance. Hypertension 1999, 33:1392-1398.
14. Pella D., Rybar R., Mechirova V. Pleiotropic effects of statins. Acta Cardiol Sin 2005, 21:190-198.
15. Blum A., Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009, 203:325-330.
16. Ludman A., Venugopal V., Yellon D.M., Hausenloy D.J. Statins and cardioprotection-more than just lipid lowering. Pharmacol Ther 2009, 122:30-43.
17. Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111-1115.
18. Sorensen K.E., Celermajer D.S., Spiegelhalter D.J., et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995, 74:247-253.
19. Joannides R., Haefeli W.E., Linder L., et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995, 91:1314-1319.
20. Franzoni F., Ghiadoni L., Galetta F., et al. Physical activity, plasma antioxidant capacity, and endothelium-dependent vasodilation in young and older men. Am J Hypertens 2005, 18:510-516.
21. Vinet A., Karpoff L., Walther G., Startun A., Obert P., Goret L., Dauzat M., Perez-Martin A. Vascular reactivity at rest and during exercise in middle-aged obese men: effects of short-term, low-intensity, exercise training. Int J Obes (Lond) 2010.
22. Thijssen D.H., van Bemmel M.M., Bullens L.M., et al. The impact of baseline diameter on flow-mediated dilation differs in young and older humans. Am J Physiol Heart Circ Physiol 2008, 295:H1594-H1598.
23. Chan M.Y., Lee C.H. Fluvastatin: efficacy and safety in reducing cardiac events. Expert Opin Pharmacother 2005, 6:1883-1895.
24. Liberopoulos E.N., Daskalopoulou S.S., Mikhailidis D.P., Wierzbicki A.S., Elisaf M.S. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin 2005, 21:231-244.
25. Scheen A.J. Clinical study of the month. The LIPS study: fluvastatin for prevention of cardiac events following percutaneous coronary angioplasty. Rev Med Liege 2002, 57:479-482.
26. Ferrara D.E., Liu X., Espinola R.G., et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003, 48:3272-3279.
27. Kowalski J., Pawlicki L., Grycewicz J., et al. Estimation of antioxidative effect of atorvastatin and fluvastatin used in primary prevention of coronary heart disease-effect on lipid peroxidation. Wiad Lek 2005, 58:386-390.
28. Tanaka K., Yasuhara M., Suzumura K., Narita H., Suzuki T. Effects of fluvastatin and its major metabolites on low-density lipoprotein oxidation and cholesterol esterification in macrophages. Jpn J Pharmacol 2001, 86:289-296.
29. Haruna Y., Morita Y., Yada T., Satoh M., Fox D.A., Kashihara N. Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant-induced arthritis. Arthritis Rheum 2007, 56:1827-1835.
30. Karter Y., Curgunlu A., Erturk N., Vehid S., Mihmanli I., Ayan F. Effects of low and high doses of atorvastatin on arterial compliance. Jpn Heart J 2003, 44:953-961.